Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation Barbara Deschler, Kristin Binek, Gabriele Ihorst, Reinhard Marks, Ralph Wäsch, Hartmut Bertz, Jürgen Finke Biology of Blood and Marrow Transplantation Volume 16, Issue 7, Pages 967-975 (July 2010) DOI: 10.1016/j.bbmt.2010.02.004 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Cumulative incidence: Relapse mortality versus NRM. Biology of Blood and Marrow Transplantation 2010 16, 967-975DOI: (10.1016/j.bbmt.2010.02.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Survival distribution according to the KI. Good pretransplantation performance retains relevance in the protracted clinical course. Biology of Blood and Marrow Transplantation 2010 16, 967-975DOI: (10.1016/j.bbmt.2010.02.004) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions